EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, D. A
Right arrow Search for Related Content
PubMed
Right arrow Articles by Smith, D. A
Evidence-Based Medicine 2005; 10:79
© 2005 BMJ Publishing Group Ltd.


Therapeutics

Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease

Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004;25:1845–52.[Abstract/Free Full Text]

Q In patients with type 2 diabetes mellitus and peripheral arterial disease (PAD), is picotamide better than aspirin for preventing all cause mortality and major cardiovascular (CV) events?

Clinical impact ratings IM/Ambulatory care ******{star} Haematology ******{star} Endrocrine ******{star}

Key Words: phthalic acids • vascular diseases • diabetes mellitus (type 2)

The first 150 words of the full text of this article appear below.

METHODS
{ebmflochart.f1}Design: randomised placebo controlled trial (Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics [DAVID] study).

{ebmclsdenvelop.f1}Allocation: concealed.*

{ebmclsdeye.f1}Blinding: blinded (clinicians, patients, data collectors, outcome assessors, and data safety and monitoring committee).*

{ebmhourglass.f1}Follow up period: 24 months.

{ebmglobe.f1}Setting: 86 centres in Italy.

{ebmpatient.f1}Patients: 1209 patients who were 40–75 years of age (mean age 64 y, 73% men) with type 2 diabetes for >=5 years and PAD (>=2 of intermittent claudication for >2 mo, loss of posterior tibial pulse in the foot, ankle/arm pressure ratio <0.90 or >1.30 in the posterior or anterior tibial artery of the foot, amputation or reconstructive surgery in patients with previous intermittent claudication, or angioplasty). Exclusion criteria included myocardial infarction (MI), stroke, or unstable angina in the previous 6 months; severe neurological or mental deficits; severe comorbid conditions that would limit life expectancy to <2 years; serum creatinine >2.0 mg/dl (176 µmol/l); pregnancy; severe uncontrolled hypertension; . . . [Full text of this article]

Donald A Smith, MD, MPH

Mount Sinai School of Medicine, New York, New York, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.